Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight

This article was originally published in The Tan Sheet

Executive Summary

New promotional campaigns for Arrid and Arm & Hammer UltraMax antiperspirants are expected to help improve sales in the category this year, CEO James Craigie said during a first quarter earnings call May 10. Revenue declines in the firm's antiperspirant/deodorant business are attributable to unsuccessful marketing initiatives and competition, the exec added. Net first quarter sales increased 42% to $420.7 mil., primarily due to the acquisition of Armkel, but rose 4% organically. Net income was up 26% to $37.7 mil. and operating profit was flat at $69.7 mil. C&D is developing a three-year growth plan that will be previewed in August during the company's second quarter earnings call...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel